Clinical Trial

The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 6, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blind, single-center, dose-escalation, single ascending dose and multiple ascending dose study of SYH9017 in Chinese participants with overweight and obesity.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-11; most recent amendment 2026-04-03.
Status change: Not Yet Recruiting → Recruiting 2025-03-04
Trial Details
NCT Number NCT06830343
Lead Sponsor CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Conditions Overweight or Obesity
Enrollment 66 participants
Start Date 2025-02-27
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-06